BUSINESS

Chugai’s PNH Med Bags World’s 1st Approval in China

February 9, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Chugai Pharmaceutical said on February 8 that China became the first country to approve its in-house discovered humanized complement inhibitor C5 monoclonal antibody crovalimab, a treatment for paroxysmal nocturnal hemoglobinuria (PNH). China’s National Medical Products Administration (NMPA) gave the green…

To read the full story

Chugai Gets Priority Review for PNH Med Crovalimab in China
August 12, 2022

BUSINESS

Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use

By Takashi Ebisawa

International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…